Biotech Venture Funding Tracker 2026
Private financings — Company, date, round, investors, therapeutic area, and a one-line
"what they do."
Last updated:
06 May 2026
Unlock the full 2026 VC tracker + get deal alerts
Subscribe (free) to access the full table and get new financings as they land — in
~5 mins/day, read by 2,000+ VC, BD&L, and public biotech investors.
No spam. Unsubscribe anytime.
2026 biotech venture funding snapshot
- 74 venture financings are now tracked in total for 2026 so far.
- Largest disclosed financing so far: Earendil Labs at US$787M disclosed, followed by Parabilis Medicines at US$305M and Beeline Medicines at US$300M.
- The 2026 tape has been broad rather than single-theme, spanning obesity / cardiometabolic, autoimmune / immunology, oncology, CNS / neuropsychiatry, genetic medicines / RNA, ophthalmology, AI-enabled platforms / biologics, longevity / epigenetic reprogramming, and tumour-microenvironment ADCs.
- A notable read-through is that investors are still funding both late-stage / near-commercial execution stories and next-generation platform or modality bets — from Phase 2/3 and launch-preparation companies to earlier AI, biologics, antibody, RNA, peptide, gene therapy, and cell therapy platforms with clear lead-asset narratives.
- The late-April / early-May update added Coultreon, Vivacta Bio, Windward Bio, Latus Bio, Cytospire, CellCentric, and Kanvas Biosciences, lifting the tracker by seven disclosed private rounds.
May 2026
Kanvas Biosciences
Series A
Date:
06-May-2026
|
Size:
US$48M
|
Therapeutic area:
Oncology / microbiome therapeutics
Investors:
Led by DCVC Bio, with participation from Gates Foundation, S32, Chugai Venture Fund, Amplify Partners, ReMY Investors & Consultants, Setpoint Medical, JAZZ Venture Partners, and existing investors including DCVC and Lions Capital
What they do:
Microbiome therapeutics company developing live biotherapeutic approaches for cancer. Proceeds will advance the company’s lead immuno-oncology drug candidate, designed to improve the efficacy of immunotherapy in solid tumours, while supporting platform development and clinical translation.
CellCentric
Series D
Date:
06-May-2026
|
Size:
US$220M
|
Therapeutic area:
Oncology / multiple myeloma
Investors:
Led by Venrock Healthcare Capital Partners, with participation from Pfizer, Fidelity Management & Research Company, Sofinnova Partners, RA Capital Management, Forbion, Janus Henderson Investors, TCGX, EQT Life Sciences, Avego BioScience Capital, Piper Heartland Healthcare Capital, Oxford Science Enterprises, Morningside, Schroders Capital, British Patient Capital, Cancer Research Horizons, M Ventures, and others
What they do:
Clinical-stage oncology biotech developing inobrodib, a first-in-class oral p300/CBP inhibitor, for multiple myeloma. The financing supports registration-enabling trials and continued development of inobrodib in advanced blood cancers, with the company also positioning around potential IPO optionality.
Cytospire Therapeutics
Series A
Date:
05-May-2026
|
Size:
£61M / US$83M
|
Therapeutic area:
Oncology / immune cell engagers
Investors:
Led by 4BIO Capital, with participation from Servier Ventures, British Business Bank, Sound Bioventures, Criteria Bio Ventures, Abingworth, LifeArc Ventures, Modi Ventures, Medical Incubator Japan, and Pathway Bioventures
What they do:
UK biotech developing differentiated multispecific immune cell engager antibodies designed to activate pan-gamma delta T cells. Proceeds will advance the company’s pipeline, including CYT X300 for EGFR-positive cancers, toward clinical proof-of-concept.
Windward Bio
Crossover Financing
Date:
04-May-2026
|
Size:
US$165M
|
Therapeutic area:
Immunology / respiratory and dermatology
Investors:
Led by OrbiMed, with participation from RA Capital Management, Janus Henderson Investors, Sanofi Ventures, Harbour BioMed, and existing investors Novo Holdings, Blue Owl Healthcare Opportunities, SR One, Omega Funds, RTW Investments, Qiming Venture Partners, Quan Capital, and Pivotal bioVenture Partners
What they do:
Clinical-stage immunology biotech developing long-acting antibody therapies for serious respiratory and dermatological diseases. Proceeds will advance anti-TSLP antibody WIN378 toward Phase 3 and support development of WIN027, a long-acting TSLP x IL-13 bispecific.
Latus Bio
Series A
Date:
04-May-2026
|
Size:
US$97M
|
Therapeutic area:
Genetic medicines / CNS gene therapy
Investors:
Series A extension led by 8VC, with participation from existing investors DCVC Bio, BioAdvance, Benjamin Franklin Technology Partners, Modi Ventures, Gaingels, and Hatch BioFund; Korea Development Bank and Helen’s Pink Sky Foundation joined as new investors
What they do:
Gene therapy company engineering AAV capsids and delivery approaches to expand gene therapy into larger patient populations. Proceeds will advance LTS-201 for Huntington’s disease toward IND submission and LTS-101 for CLN2 disease toward initial clinical data.
April 2026